

The Journal of **Alternative** and **Complementary Medicine**

Journal of Alternative and Complementary Medicine: <http://mc.manuscriptcentral.com/jaltcompmed>

Improvement of somatic cervical pain and disability after the application of TENS device (TANIX®)

Journal:	<i>Journal of Alternative and Complementary Medicine</i>
Manuscript ID:	Draft
Manuscript Type:	Original Articles
Date Submitted by the Author:	n/a
Complete List of Authors:	Lauretti, Gabriela; School of Medicine of Ribeirão Preto- University of São Paulo, Biomech Med Rehab Locom Mmembers Mattos, Anita; School of Medicine of Ribeirão Preto, University of São Paulo, Biomech Med Rehabil Locomotor Members Parada, Flavia; School of Medicine of Ribeirão Preto, University of São Paulo, Biomech Med Rehabil Locomotor Members Righeti, Claudia; School of Medicine of Ribeirão Preto, University of São Paulo, Biomech Med Rehabil Locomotor Members
Keywords:	pain, anesthesia, backpain
Abstract:	<p>Objectives: Cervical facet joints and neck muscles are common nociceptive pain generator, with neck and shoulder muscles pain, and limited retroflexion. We tested the hypothesis that the new TENS device (TANYX®) would relieve cervical somatic pain.</p> <p>Design: prospective double-blind randomized.</p> <p>Settings: Teaching Hospital, School of Medicine of Ribeirão Preto, university of São Paulo</p> <p>Subjects: 44 patients with chronic cervical pain patients with somatic pain, but without radicular symptoms.</p> <p>Interventions: TANYX® or placebo device was placed above C7-T1 spinous process, perpendicular to the spine, for 20-min at 12-hour interval during 3-days. The two groups were: placebo group (PG), with a sham device and the active TENS group (TG), which produced a mixed (85 Hz) frequency of stimulation, conventional, and burst. Diclofenac up to three times daily was available.</p> <p>Outcome measures: Efficacy measures were pain relief, rescue analgesics and neck disability.</p> <p>Results: The active TENS device induced pain relief after its first application, which persisted during the 3-day treatment. By the end of the TENS application, the capability of rotation, lateral extension and retroflexion were improved ($p < 0.05$). The pain score and rescue analgesics consumption reduced in the TG ($p < 0.01$, $p < 0.05$, respectively), and the mean pain score dropped from 8 to 3 points ($p < 0.01$). There were no adverse events.</p> <p>Conclusions: Somatic cervical pain and disability improved after active TENS application during the three consecutive days, which persisted upon</p>

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

	the 1-month reevaluation.

SCHOLARONE™
Manuscripts

1
2
3 **Improvement of somatic cervical pain and disability after the application of TENS device**
4 **(TANIX®)**
5

6
7 Gabriela R Lauretti, M.D., M.Sc., Ph.D., F.I.P.P.¹

8
9 Flavia Parada, Physioterapist²

10
11 Anita L Mattos, M.D., M.Sc., Ph.D.³

12
13 Claudia CF Righeti, M.D., M.Sc.²

14
15 1 Associate Professor of Anesthesiology and Pain Management, School of Medicine of
16
17 Ribeirão Preto- University of São Paulo, Brazil

18
19 2 Postgraduate Student in Anesthesiology and Pain Management, School of Medicine of
20
21 Ribeirão Preto- University of São Paulo, Brazil

22
23 3 Assistant Professor of Anesthesiology and Pain Management, School of Medicine of
24
25 Ribeirão Preto- University of São Paulo, Brazil

26
27
28
29 **Corresponding author:**

30
31 Gabriela R Lauretti

32
33 Rua-Maestro Joaquim Rangel, 644

34
35 Ribeirão Preto- São Paulo Brazil- ZIP14025-610

36
37 Fax: 010 55 16 602 2211

38
39 Phone: 010 55 16 602 22 11 (hospital)

40
41 Email- grlauret@fmrp.usp.br

42
43
44 **Running head:** Cervical pain relief after TENS

45
46 **Key-words:** cervical somatic pain, neck disability, TENS

Abstract

Objectives: Cervical facet joints and neck muscles are common nociceptive pain generator, with neck and shoulder muscles pain, and limited retroflexion. We tested the hypothesis that the new TENS device (TANYX®) would relieve cervical somatic pain.

Design: prospective double-blind randomized.

Settings: Teaching Hospital, School of Medicine of Ribeirão Preto, university of São Paulo

Subjects: 44 patients with chronic cervical pain patients with somatic pain, but without radicular symptoms.

Interventions: TANYX® or placebo device was placed above C7-T1 spinous process, perpendicular to the spine, for 20-min at 12-hour interval during 3-days. The two groups were: placebo group (PG), with a sham device and the active TENS group (TG), which produced a mixed (85 Hz) frequency of stimulation, conventional, and burst. Diclofenac up to three times daily was available.

Outcome measures: Efficacy measures were pain relief, rescue analgesics and neck disability.

Results: The active TENS device induced pain relief after its first application, which persisted during the 3-day treatment. By the end of the TENS application, the capability of rotation, lateral extension and retroflexion were improved ($p < 0.05$). The pain score and rescue analgesics consumption reduced in the TG ($p < 0.01$, $p < 0.05$, respectively), and the mean pain score dropped from 8 to 3 points ($p < 0.01$). There were no adverse events.

Conclusions: Somatic cervical pain and disability improved after active TENS application during the three consecutive days, which persisted upon the 1-month reevaluation.

1
2
3 **Improvement of somatic cervical/shoulder pain and disability after the application of**
4
5
6 **TENS device (TANIX)**
7
8
9

10
11 **Introduction**
12

13 Cervical facet joints and neck muscles have been well ascertained in the literature
14 as a customary nociceptive pain producer, with a projected prevalence that ranges from
15 up to 66% of chronic axial neck pain¹. The most ordinary symptom is pain without
16 radiation to the arm, however linked with neck and shoulder muscles pain, while turning
17 and retroflexion are habitually painful or narrow.^{1,2} We tested the hypothesis that the
18 new TENS device (TANYX®) would relieve cervical pain, both facet and muscle pain,
19 examples of nociceptive somatic pain.
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Materials and Methods

The local Ethics Committee approved the study protocol, and informed consent was obtained from all patients. In this prospective, randomized, double-blinded, controlled study we studied 44 chronic cervical pain patients without radicular symptoms with insufficient pain relief (visual analogue scale (VAS) >4) treated with standardized analgesic therapy, with diagnosis of painful neck muscle combined with cervical facet pain.

All patients rated pain on average ≥ 4 cm on a VAS, taking no other drugs apart analgesics such as metamizol, paracetamol or cyclobenzaprine, enrolled at the Center for Pain Treatment- Teaching Hospital were potentially qualified for inclusion. Diagnosis of nonappearance of radicular neuropathic and proof of nociceptive somatic pain was settled based on the clinical history and examination combined with cervical magnetic resonance to reject any pathologies. Patients were unqualified for the study if they had experienced surgery for radiculopathy within the last 3 months; if they had been once treated with TENS, suffered from dizziness, if they used non-steroidal anti-inflammatory drugs for the last 14-day prior to entrance into the study protocol, if they had agonized cervical pain for less than 3 months; if cervical pain was coupled with radiculopathy; if any surgery was anticipated within the next 6 months; if they had a pacemaker; if they were naive of non-pharmacological treatments including physiotherapy, acupuncture, mesotherapy, manipulations, wearing a corset, or psychological support; if their cervical was indicative of another condition (i.e., compression fractures or progressive inflammatory, neoplastic or infectious conditions); if the physician had appraised their life expectancy to be less

1
2
3 than 3 months; and finally if articular, median branches, epidural or foraminal blocks were
4
5
6 planned during the study period, or if the patient was involved in an ongoing medico-legal
7
8
9 dispute.

10
11 Either the new, very small and light, high frequency TENS device (TANYX®), or
12
13 placebo device was placed centrally at the space between the C7 and T1 spinous
14
15 processes, perpendicular to the spine, for 20-min at 12-hour interval during 3-days.³
16
17
18 Patients were randomly divided into two groups (n=22). For the placebo group (PG), the
19
20 device did not transmitted electrical stimulus, although it was externally similar to the
21
22 active one. The other patients applied the active TENS device (TG), which produced a
23
24 conventional TENS characterized by continuous stimulation at high frequency (85 Hz),
25
26 wave duration of 75 μ s and intensity of up to 30 mA, potentially achieving painless
27
28 paraesthesia only in the cervical region or tingling sensation. It was explained to patients
29
30 not to obtain cervical muscle contraction, but only paresthesia feeling. Diclofenac (50 mg)
31
32 up to three times daily was used as rescue analgesic if necessary for pain control. The
33
34 efficacy measures were pain relief evaluated on: 1) a VAS scale, 2) reduction in use of
35
36 rescue analgesics, 3) capability of rotation, lateral extension and retroflexion of the neck,
37
38 and 4) capacity of performing routine physical activities, defined as maintained, improved,
39
40 or worsened.
41
42
43
44
45
46
47

48 **Statistics**

49
50 We hypothesized that 100% of the patients receiving TENS twice daily would
51
52 achieve a decrease of at least 50% on the pain VAS compared with baseline pain. On this
53
54 basis, with an alpha of 5%, it was calculated that at least 18 evaluable patients would be
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

needed to achieve an 80% power to detect any effect of TENS. Data was compared between groups by Kruskal Wallis when evaluating numerical data, and chi-squared test for qualitative variables. $P < 0.05$ was considered significant.

Results

Patients were demographically similar related to age, American Society of Anesthesiology status (ASA), weight, height and gender ($p>0.05$, Table 1). One patient from the PG failed to complete data collection and was withdrawn from the final data evaluation.

The active TENS device induced gradually pain relief in 20 of 22 patients after its first application, which persisted during the three-day treatment. Two patients from the TG turned the active TENS device on until obtaining cervical muscle contraction, instead of obtaining only paresthesia, and were more painful after the first day. The pain score was significantly reduced in the TG compared to the PG ($p<0.01$), and the mean pain score dropped from 8 to 3 points ($p<0.01$, Table 2) to the TG.

Concurrent use of analgesic tablets was also reduced ($p<0.05$) in the TG compared to the PG and six patients stopped taking analgesics while using the active device ($p<0.05$, Table 2).

There were no difference between two groups in cervical activity in all directions before treatment ($P > 0.05$). By the end of the TENS application, the capability of rotation, lateral extension and retroflexion were worldly improved in the TG ($p<0.05$). The capacity of performing routine physical activities during these three day-evaluation were defined as improved in 20 of 22 patients in the TG ($p<0.05$, Table 3). In the PG, 19 of 21 patients referred maintenance of worsening of cervical disability and capacity of performing routine daily activities, while two patients the PG described as improved, although they maintained the daily rescue analgesic consumption ($p<0.05$, Table 3).

1
2
3 Twenty TG participants subjectively found the device useful. There were no
4
5
6 adverse events. On follow-up 1-month post-study, the twenty patients from the TG still
7
8 referred improvement in neck pain and disability. Apart from local cervical muscle pain
9
10 after inappropriate device application in the two patients from the TG, three patients
11
12 observed itching sensation on the local of application. No other adverse effects were
13
14 observed in any of the groups.
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Discussion

A literature search regarding neck pain revealed inconsistent results and low quality evidence for cervical TENS up to date⁴. One of the reasons could be the lack of separation of the neuropathic and somatic type of pain, as it has been demonstrated that active TENS was effective only after somatic, but not neuropathic pain.^{5,6} Another reason could be the intensity of the neck pain. The TENS treatment was demonstrated to be effective for neck pain due to musculoskeletal disorders with subjects who have a mild neck pain rather than those with severe symptoms.⁷ In this actual study we found that patients suffering from cervical articular facet and neck muscle pain, that are examples of pure somatic type of pain, improved pain and disability after the active TENS daily application during the three consecutive days, which persisted at the one-month reevaluation, combined to a lesser rescue daily analgesic consumption during the three-day evaluation, maintained up to one month evaluation. All patients from both groups reported a VAS pain qualified as 8-cm, which was considered strong, although not the strongest, probably in accordance to others⁷

Among the mechanisms involved, TENS efficacy appears to be mediated by the release of mu- or delta-opioids³, and involve its ability to increase the vibration threshold probably due to distraction or antidromic block of large-diameter nerve fibres⁸. In addition, TENS analgesia appears to be caused mainly by differentially blocking the activation of large diameter primary afferents from deep somatic tissues, and not cutaneous afferents.⁹ High frequency-TENS, as the device we used, was described capable of inducing analgesia, which was most likely related to increased serotonin release and

1
2
3 also to block the adverse cardiovascular and respiratory changes induced by pain.¹⁰ A
4
5 superior mechanism of action was also identified through the periaqueductal gray that
6
7 sends projections through the rostroventralmedial medulla to the spinal cord to produce
8
9 an opioid-mediated analgesia.¹¹
10
11

12
13 In the actual study, all patients used the TENS device for three-days, twice daily,
14
15 during 20-min, where patients from the TG applied 85 Hz frequency, wave duration of 75
16
17 μ s and intensity of up to 30 mA. Tolerance to the TENS have been suggested before,
18
19 although with much higher currents with pulse duration (110 μ s), and pulse frequencies in
20
21 healthy volunteers, during two consecutive days. However the authors found no ideal
22
23 frequency *versus* time interaction and time-dependent for the outcome measures.¹²
24
25 Other authors demonstrated that in rats, repeated administration of modulating
26
27 frequency TENS lead to the development of opioid tolerance, which was delayed by
28
29 approximately 5 days after low- or high-frequency TENS independently.³ Because we used
30
31 the device for only three days with good results, we did not expect any tolerance effects
32
33 development.
34
35
36
37
38
39

40
41 Recent trial revealed a better therapeutic effect obtained by combining traction
42
43 with TENS in cervical spinal pain.¹³ However neither neck manipulation, wearing neck
44
45 collar, nor neck rehabilitation exercises were applied in the actual study during the one-
46
47 month evaluation, in order to not interfere with the final results. Manipulation of
48
49 miofascial trigger points were also not done as interactive neurostimulation therapy
50
51 associated with myofascial trigger points in adults with mechanical neck pain was
52
53
54
55
56
57
58
59
60

1
2
3 demonstrated effective¹⁴ or at least similar when comparing manual therapy to TENS.¹⁵
4

5
6 Again, no manual neck handling was included in the study protocol, in order to avoid bias.
7

8
9 Although the active TENS device was extremely effective in 20 of 22 patients, two
10 patients applied the device with such an increased intensity that caused cervical muscles
11 contraction and pain. Any TENS device is always supposed to be applied with enough
12 intensity to obtain paresthesia only which recruits β -fibers, and $A\alpha$ -fibers recruitment¹⁶,
13 what would result and muscle contraction and resultant pain. These patients continued
14 the evaluation up to one month and complained of worse pain, although the device was
15 correctly applied on the second and third days. Another interesting aspect is the itching
16 sensation after TENS, observed by three patients in the TG, as described by other¹⁷,
17 although, controversially, TENS was also used to treat pruritus¹⁸, with unfortunately
18 unknown mechanisms.
19
20
21
22
23
24
25
26
27
28
29
30
31
32

33
34 Regarding the capability of rotation, lateral extension and neck retroflexion, and
35 capacity of performing routine physical activities, all patients who correctly applied the
36 TENS device at C7-T1 improved, in accordance to others.⁴ Few patients with cervical pain
37 may complain of dizziness, what was not our case because of the exclusion criteria. TENS
38 was found to influence cardiovascular responses by alleviating sympathetic activity^{10,19}, to
39 enhance visuospatial abilities and postural control¹⁹, what would benefit patients. In our
40 study, device was applied over C7-T1 dorsal spine, as the location of TENS electrodes is
41 crucial for obtaining the strongest pain relief²⁰ Significant tinnitus suppression was
42 described after lower frequency TENS applied for 30 min at the C2 level.²¹
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Conclusions

In conclusion, this active TENS device resulted in effective treatment alternative for nociceptive somatic cervical/neck pain, with no serious adverse effects when correctly applied.

Review Only; Not for Distribution

1
2
3 **Acknowledgments**
4

5
6 The authors thank FARMOQUIMICA SA -Brazil for Tanyx and placebo donations. Other
7
8 costs of the study were supported by the Center for Pain Management- HC- FMRP-USP.
9
10
11 Teaching Hospital, School of Medicine of Ribeirão Preto, University of São Paulo, Brazil.
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References

1. Kirpalani D, Mitra R. Cervical facet joint dysfunction: a review. *Arch Phys Med Rehabil* 2008;89:770-4.
2. Jensen I, Harms-Ringdahl K. Strategies for prevention and management of musculoskeletal conditions. Neck pain. *Best Pract Res Clin Rheumatol* 2007;21:93-108.
3. Desantana JM, Santana-Filho VJ, Sluka KA. Modulation between high- and low-frequency transcutaneous electric nerve stimulation delays the development of analgesic tolerance in arthritic rats. *Arch Phys Med Rehabil* 2008;89:754-60.
4. Kroeling P1, Gross A, Graham N, Burnie SJ, Szeto G, Goldsmith CH, Haines T, Forget M. Electrotherapy for neck pain. *Cochrane Database Syst Rev* 2013;8:CD004251.
5. Lauretti GR, Chubaci EF, Mattos AL. Efficacy of the use of two simultaneously TENS devices for fibromyalgia pain. *Rheumatol Int* 2013;33:2117-22.
6. Buchmuller A, Navez M, Milletre-Bernardin M, Pouplin S, Presles E, Lantéri-Minet M, Tardy B, Laurent B, Camdessanché JP; Lombotens Trial Group. Value of TENS for relief of chronic low back pain with or without radicular pain. *Eur J Pain* 2012;16:656-65.
7. Maayah M1, Al-Jarrah M. Evaluation of Transcutaneous Electrical Nerve Stimulation as a Treatment of Neck Pain due to Musculoskeletal Disorders. *J Clin Med Res* 2010;2:127-36.

- 1
2
3 8. Palmer S, Cramp F, Propert K, Godfrey H. Transcutaneous electrical nerve
4 stimulation and transcutaneous spinal electroanalgesia: a preliminary efficacy and
5 mechanisms-based investigation. *Physiotherapy* 2009;95:185-91.
6
7
- 8
9
10 9. Radhakrishnan R, Sluka KA. Deep tissue afferents, but not cutaneous afferents,
11 mediate transcutaneous electrical nerve stimulation-Induced antihyperalgesia. *J*
12 *Pain* 2005;6:673-80.
13
14
- 15
16
17 10. Santuzzi CH, Neto Hde A, Pires JG, Gonçalves WL, Gouvea SA, Abreu GR. High-
18 frequency transcutaneous electrical nerve stimulation reduces pain and cardio-
19 respiratory parameters in an animal model of acute pain: participation of
20 peripheral serotonin. *Physiother Theory Pract* 2013;29:630-8.
21
22
- 23
24
25 11. DeSantana JM, Da Silva LF, De Resende MA, Sluka KA. Transcutaneous electrical
26 nerve stimulation at both high and low frequencies activates ventrolateral
27 periaqueductal grey to decrease mechanical hyperalgesia in arthritic rats.
28 *Neuroscience* 2009;163:1233-41.
29
30
- 31
32
33 12. Karakaya IC¹, Karakaya MG, Erğün E, Elmalı S, Fırat T. Effects of different
34 frequencies of conventional transcutaneous electrical nerve stimulation on
35 pressure pain threshold and tolerance. *J Back Musculoskelet Rehabil* 2013 [Epub
36 ahead of print]
37
38
- 39
40
41 13. Myśliwiec A, Saulicz E, Kuszewski M, Wolny T, Saulicz M, Knapik A.
42
43
44 The effect of Saunders traction and transcutaneous electrical nerve stimulation on
45 the cervical spine range of motion in patients reporting neck pain - pilot study.
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
60 *Ortop Traumatol Rehabil* 2012;14:515-24.

- 1
2
3 14. Schabrun SM¹, Cannan A, Mullens R, Dunphy M, Pearson T, Lau C, Chipchase LS.
4
5 The effect of interactive neurostimulation therapy on myofascial trigger points
6
7 associated with mechanical neck pain: a preliminary randomized, sham-controlled
8
9 trial. *J Altern Complement Med* 2012;18:946-52.
10
11
12
13 15. Escortell Mayor E¹, Lebrijo Pérez G, Pérez Martín Y, Asúnsolo del Barco A, Riesgo
14
15 Fuertes R, Saa Requejo C; TEMA-TENS Group. Randomized clinical trial for primary
16
17 care patients with neck pain: manual therapy versus electrical stimulation. *Aten*
18
19 *Primaria* 2008;40:337-43.
20
21
22
23 16. Yang F¹, Chung CY, Wacnik PW, Carteret AF, McKelvy AD, Meyer RA, Raja SN, Guan
24
25 Y. Electrical stimulation at distinct peripheral sites in spinal nerve injured rats leads
26
27 to different afferent activation profiles. *Neurosci Lett* 2011;505:52-7.
28
29
30
31 17. Ozawa M¹, Tsuchiyama K, Gomi R, Kurosaki F, Kawamoto Y, Aiba S. Neuroselective
32
33 transcutaneous electric stimulation reveals body area-specific differences in itch
34
35 perception. *J Am Acad Dermatol* 2006;55:996-1002.
36
37
38
39 18. Yüksek J¹, Sezer E, Aksu M, Erkokmaz U. Transcutaneous electrical nerve
40
41 stimulation for reduction of pruritus in macular amyloidosis and lichen simplex. *J*
42
43 *Dermatol* 2011;38:546-52.
44
45
46 19. Chu H¹, Li MH, Juan SH, Chiou WY. Effects of transcutaneous electrical nerve
47
48 stimulation on motion sickness induced by rotary chair: a crossover study. *J Altern*
49
50 *Complement Med* 2012;18:494-500.
51
52
53 20. Buonocore M¹, Camuzzini N, Cecini M, Dalla Toffola E. High-frequency
54
55 transcutaneous peripheral nerve stimulation induces a higher increase of heat pain
56
57
58
59
60

1
2
3 threshold in the cutaneous area of the stimulated nerve when confronted to the
4
5
6 neighbouring areas. Biomed Res Int 2013;2013:464207.

- 7
8
9 21. Vanneste S19., Plazier M, Van de Heyning P, De Ridder D. Transcutaneous electrical
10
11 nerve stimulation (TENS) of upper cervical nerve (C2) for the treatment of somatic
12
13 tinnitus. Exp Brain Res 2010;204:283-7.
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1. Demographic data.

	Age (years)	ASA I/II	Weight (kg)	Height (cm)	Gender (M/F)
PG	42±6	9-I	72±12	172±6	13-M
		12-II			8-F
TG	44±8	8-I	78±9	175±7	12- M
		14-II			10-F

PG- placebo group; TG- TENS group

ASA- American Society of Anesthesiology (p>0.05).

Table 2. Pain measurements.

	Prior VAS (cm)*	VAS after TENS*	Prior n°. of diclofenac tablets*	N°. diclofenac tablets after TENS*
PG	8(7-9)	8(6-9)	2(2-3)	2(2-3)
TG	8(7-9)	3(2-4)	2(2-3)	1(0-2)
p (between groups)	p>0.05	P<0.01	p>0.05	P<0.05

*Data expressed as mean (25%-75% percentile); VAS- visual analog scale

Table 3. Neck disability and capacity of performing routine daily activities after 3-day TENS device.

	Capability of neck rotation	Capability of neck lateral extension	Capability of neck retroflexion	Capacity of performing routine activities
PG	15- maintained 4- worsened 2- improved	14- maintained 5- worsened 2- improved	15- maintained 4- worsened 2- improved	15- maintained 4- worsened 2- improved
TG	20- improved 2- worsened	20- improved 2- worsened	20- improved 2- worsened	20- improved 2- worsened

PG- placebo group; TG- TENS group; $p < 0.05$ between groups